P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting

MLA

M. Moezi, et al. “P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-World Setting.” Journal of Thoracic Oncology, vol. 12, Nov. 2017, pp. S1913–14. EBSCOhost, https://doi.org/10.1016/j.jtho.2017.09.705.

APA

M. Moezi, Cory Batenchuk, Edward B. Garon, Mark D. Danese, Donald A. Richards, Sharon Wilks, David R. Spigel, Deborah P. Lubeck, V. Gunuganti, Virginia Burns, Maen A. Hussein, Robert M. Jotte, Jason C. Chandler, Michelle Gleeson, David M. Waterhouse, & Beata Korytowsky. (2017). P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting. Journal of Thoracic Oncology, 12, S1913–S1914. https://doi.org/10.1016/j.jtho.2017.09.705

Chicago

M. Moezi, Cory Batenchuk, Edward B. Garon, Mark D. Danese, Donald A. Richards, Sharon Wilks, David R. Spigel, et al. 2017. “P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-World Setting.” Journal of Thoracic Oncology 12 (November): S1913–14. doi:10.1016/j.jtho.2017.09.705.